Qualisure News

Unique Thyroid Cancer Tests: New Hope Unveiled

Precision Oncology Test Thyroid GuidePx® Now Available From Qualisure Diagnostics

Qualisure submits an international PCT patent application for the molecular subclassification of papillary thyroid cancer

Qualisure is awarded a $100,000 Voucher grant from Alberta Innovates

University of Calgary invests $150,000 in Qualisure through the UCeed Health Fund

Dr. Oliver Bathe (CEO) and collaborators are awarded the Jennifer Gardiner Award in Surgical Oncology Research

Qualisure announces partnership with Orlando, Florida-based Protean BioDiagnostics Inc.

Qualisure partners with Calgary, Alberta-based OncoHelix Inc.

Qualisure is awarded a $295,000 AICE-Validate grant from Alberta Innovates

Qualisure Diagnostics Inc. acquires an array of intellectual property from Innovate Calgary

Prognostication with Thyroid GuidePx in the context of tall cell variants

Abstract: RAI GuidePx: A robust predictor for radioactive iodine sensitivity status in papillary thyroid cancer leveraging thyroid differentiation genes.

Abstract: Molecular subtypes in radiation induced papillary thyroid cancer using Thyroid GuidePx.

The Technological Drivers Powering Precision Oncology

Unique Thyroid Cancer Tests: New Hope Unveiled

Understanding Radioactive Iodine Resistance in Thyroid Cancer: Overcoming Treatment Challenges

Subscribe For Updates on Testing & Diagnostics

Sign up to receive updates from Qualisure regarding our latest developments in precision medicine tools.

First Name

Last Name

Email Address

Telephone

Organization

Country

I am a(n)

consent_sub

I consent to the use of my personal information for the purpose of receiving updates and communications about the latest developments in Precision Oncology.

Get Started

Thyroid GuidePx®

News

Investors